Chronic lymphocytic leukemia explained: symptoms and treatment

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. It develops when a specific type of white blood cell called lymphocytes grows abnormally and accumulates over time.

Lymphocytes play an important role in the immune system because they help the body fight infections. In CLL, these cells become cancerous and multiply in an uncontrolled way. However, unlike aggressive leukemias, CLL usually progresses slowly.

CLL is considered a chronic condition because it develops gradually and may not require immediate treatment in some cases. Many patients live with the disease for years while being monitored by healthcare professionals.

Symptoms of Chronic lymphocytic leukemia

In the early stages, CLL often does not cause noticeable symptoms. Some people discover it accidentally during routine blood tests.

When symptoms appear, they may include:

• Persistent fatigue or weakness
• Swollen lymph nodes in the neck, armpits, or groin
• Unexplained weight loss
• Frequent infections
• Fever without obvious infection
• Night sweats
• Enlarged spleen, which may cause discomfort or a feeling of fullness in the abdomen
• Easy bruising or bleeding
• Shortness of breath in more advanced stages

These symptoms occur because abnormal lymphocytes accumulate in the blood, bone marrow, and lymphatic system, interfering with normal blood cell production and immune function.

It is important to consult a doctor if symptoms persist or worsen over time.

Causes and Risk Factors

The exact cause of CLL is not fully understood. It happens when genetic changes occur in lymphocytes, causing them to multiply abnormally and avoid normal cell death.

Researchers believe that a combination of genetic and environmental factors may contribute to its development.

Risk Factors

• Age: CLL is more common in people over 60 years old.
• Family history: Having a close relative with CLL or another blood cancer increases the risk.
• Gender: Men are slightly more likely to develop CLL than women.
• Exposure to certain chemicals: Long-term exposure to specific industrial chemicals may increase risk.
• Genetic mutations: Changes in DNA within lymphocytes play a key role in disease development.

However, many people diagnosed with CLL have no clear identifiable risk factor.

Diagnosis of Chronic lymphocytic leukemia

CLL is usually diagnosed through blood tests and specialized laboratory examinations.

Blood Tests

A complete blood count (CBC) is often the first test that shows abnormal results. Doctors may notice:

• High number of lymphocytes
• Abnormal white blood cell count

If lymphocyte levels are elevated, additional testing is required to confirm the diagnosis.

Flow Cytometry

Flow cytometry is a laboratory test that analyzes blood cells to determine whether the lymphocytes are cancerous and to identify their specific characteristics. This test helps confirm CLL.

Bone Marrow Examination

In some cases, doctors may perform a bone marrow biopsy to evaluate how much the disease has affected blood cell production.

Imaging Tests

Imaging tests such as ultrasound, CT scan, or PET scan may be used to:

• Assess enlarged lymph nodes
• Check spleen enlargement
• Evaluate the spread of the disease

Genetic Testing

Doctors may also perform genetic and molecular tests to identify specific mutations. These results help guide treatment decisions and predict how the disease may progress.

Diagnosis usually involves combining blood results, laboratory testing, and clinical evaluation.

Staging of Chronic lymphocytic leukemia

After diagnosis, doctors determine the stage of the disease. Staging helps assess how advanced the cancer is and whether treatment is necessary.

The two main staging systems are:

• Rai system
• Binet system

These systems evaluate factors such as:

• Lymph node enlargement
• Spleen enlargement
• Anemia (low red blood cells)
• Low platelet count

Early-stage CLL may not require immediate treatment and is often monitored regularly. Advanced stages usually require active treatment.

Treatment of Chronic lymphocytic leukemia

Treatment for CLL depends on:

• Disease stage
• Symptoms
• Blood test results, Genetic markers
• Patient age and overall health

Some patients do not need treatment at the time of diagnosis and only require regular monitoring.

Watchful Waiting

If CLL is stable and not causing significant symptoms, doctors may recommend observation instead of immediate treatment.

During this period:

• Regular blood tests are performed
• Physical exams monitor lymph nodes and spleen
• Symptoms are tracked closely

Treatment begins if the disease progresses or symptoms worsen.

Active treatment options

Treatment for chronic lymphocytic leukemia (CLL) is not always required immediately after diagnosis. However, when the disease progresses, causes symptoms, or shows signs of aggressive behavior, active treatment becomes necessary.

The choice of treatment depends on several factors, including:

• The stage of the disease
• Genetic mutations and laboratory results
• The patient's age and overall health
• The presence of symptoms
• Response to previous treatments (if applicable)

Today, treatment options are more advanced and personalized compared to the past. Doctors usually select therapies based on disease characteristics and patient-specific factors.

Targeted Therapy

Targeted therapy is one of the most important advances in CLL treatment. Instead of killing all rapidly dividing cells like traditional chemotherapy, targeted drugs focus on specific molecules or pathways that help cancer cells survive and multiply.

These medications block signals that allow leukemia cells to grow and resist death.

Common targeted treatment groups include:

BTK Inhibitors

These drugs block a protein called Bruton's tyrosine kinase (BTK), which plays a key role in the survival of CLL cells. By blocking this protein, the medication prevents cancer cells from growing and spreading in the body.

BTK inhibitors are often taken as oral medications and are used as first-line treatment or in relapsed cases.

BCL-2 Inhibitors

BCL-2 is a protein that helps cancer cells avoid natural cell death. In CLL, this protein is often overactive; it works by restoring the normal process of cell death, allowing leukemia cells to die naturally.

These drugs are frequently combined with other therapies to improve effectiveness.

Immunotherapy

Immunotherapy strengthens or modifies the body's immune system so it can recognize and destroy cancer cells more effectively.

In CLL, immunotherapy commonly includes:

Monoclonal Antibodies

These are laboratory-made antibodies that attach to specific proteins on the surface of leukemia cells. Once attached, they mark the cancer cells for destruction by the immune system.

Monoclonal antibodies are often used:

• In combination with targeted therapy
• Together with chemotherapy
• As part of first-line or relapse treatment

Chemotherapy

Chemotherapy uses medications that destroy rapidly dividing cells, including cancer cells.

In CLL, chemotherapy is not used as frequently as before because targeted therapies have shown better effectiveness and fewer long-term side effects. However, it may still be used in specific situations.

Chemotherapy is often combined with:

• Immunotherapy
• Targeted therapy

This combination approach improves treatment response in some patients.

Common side effects of chemotherapy include:

• Hair thinning or hair loss
• Fatigue
• Nausea and vomiting
• Lowered blood counts
• Increased infection risk

Combination Therapy

Many patients receive combination therapy rather than a single drug. Combination treatment may include:

• Targeted therapy + immunotherapy
• Targeted therapy + short-course chemotherapy
• Dual targeted agents in specific high-risk cases

The goal of combination therapy is to increase treatment effectiveness, reduce the risk of resistance and improve long-term disease control. Treatment plans are highly individualized based on genetic markers and disease progression.

Stem cell transplant

Stem cell transplantation is not a common treatment for most people with CLL. It is usually considered only in specific high-risk cases or when the disease does not respond to other therapies.

Before the transplant:

• High-dose therapy is used to eliminate cancer cells
• Healthy stem cells are infused to rebuild the bone marrow

This procedure carries significant risks, including infections and immune complications, so it is reserved for selected patients.

Treatment for relapsed or refractory CLL

Some patients may experience relapse, meaning the disease returns after treatment. Others may not respond adequately to initial therapy (refractory disease).

In these cases, doctors may:

• Switch to another targeted drug
• Use a different drug combination
• Adjust treatment based on new genetic testing results

Advances in modern therapies have improved outcomes even for relapsed CLL.

Supportive care during treatment

Alongside active cancer treatment, supportive care plays an essential role.

Supportive measures include:

• Antibiotics or antiviral medications to prevent or treat infections
• Vaccinations as recommended by specialists
• Blood transfusions if anemia or low platelets occur
• Growth factors to stimulate blood cell production
• Management of treatment side effects

Conclusion

Chronic lymphocytic leukemia is a slow-growing blood cancer that mainly affects older adults. In many cases, it progresses gradually and may not require immediate treatment. Understanding the disease, its symptoms, and available treatment options helps patients manage it effectively. Regular monitoring, modern targeted therapies, and personalized medical care have greatly improved survival and quality of life for people living with CLL.

If diagnosed early and managed properly, many individuals can continue their daily lives with minimal disruption while staying under medical supervision.